Hepatitis C: the clinical spectrum of the disease (Q33809411)

29 July 2017

1 reference

title

Hepatitis C: the clinical spectrum of the disease (English)

1 reference

29 July 2017

1 reference

Marcellin P

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

31 Suppl 1

1 reference

29 July 2017

page(s)

9-16

1 reference

Epidemiology of Hepatitis C in the West

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Clinical course of acute hepatitis C and changes in HCV markers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C virus viremia following clinical resolution of acute hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Histological findings in asymptomatic hepatitis C virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Histological evolution of chronic hepatitis C. Factors related to progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C and Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Extrahepatic Manifestations of Hepatitis C and the Association with Alcoholic Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980368-7

7 January 2021

10.1016/S0168-8278(99)80368-7

Identifiers

DOI

1 reference

29 July 2017

1 reference